Biotech Values

[iwfal]

Lilly's peglispo - safety profile. The T1D safety results you highlighted look similar to those seem in the T2D trial. Somewhat worse lipid profile, increased liver fat and ALT. But there were also some differences. In T1D there was weight loss (vs weight gain for lantus) and more total hypoglycemia albeit while reducing nocturnal hypo.

In toto the peglispo looks more like another option than a real improvement over lantus. But need to see the complete data.